Unknown

Dataset Information

0

Local Stabilization of Hypoxia-Inducible Factor-1? Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation.


ABSTRACT: Intestinal epithelial cells are adapted in mucosal hypoxia and hypoxia-inducible factors in these cells can fortify barrier integrity to support mucosal tissue healing. Here we investigated whether hypoxia-related pathways could be proposed as potential therapeutic targets for inflammatory bowel disease. We developed a novel hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, CG-598 which stabilized HIF-1? in the gut tissue. Treatment of CG-598 did not affect extra-intestinal organs or cause any significant adverse effects such as erythropoiesis. In the experimental murine colitis model, CG-598 ameliorated intestinal inflammation with reduction of inflammatory lesions and pro-inflammatory cytokines. CG-598 treatment fortified barrier function by increasing the expression of intestinal trefoil factor, CD73, E-cadherin and mucin. Also, IL-10 and IL-22 were induced from lamina propria CD4+ T-cells. The effectiveness of CG-598 was comparable to other immunosuppressive therapeutics such as TNF-blockers or JAK inhibitors. These results suggest that CG-598 could be a promising therapeutic candidate to treat inflammatory bowel disease.

SUBMITTER: Kim YI 

PROVIDER: S-EPMC7840603 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation <i>via</i> Enhanced Gut Barrier Function and Immune Regulation.

Kim Young-In YI   Yi Eun-Je EJ   Kim Young-Dae YD   Lee A Reum AR   Chung Jiwoung J   Ha Hae Chan HC   Cho Joong Myung JM   Kim Seong-Ryeol SR   Ko Hyun-Jeong HJ   Cheon Jae-Hee JH   Hong Yong Rae YR   Chang Sun-Young SY  

Frontiers in immunology 20210114


Intestinal epithelial cells are adapted in mucosal hypoxia and hypoxia-inducible factors in these cells can fortify barrier integrity to support mucosal tissue healing. Here we investigated whether hypoxia-related pathways could be proposed as potential therapeutic targets for inflammatory bowel disease. We developed a novel hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, CG-598 which stabilized HIF-1α in the gut tissue. Treatment of CG-598 did not affect extra-intestinal organs or  ...[more]

Similar Datasets

| S-EPMC5592826 | biostudies-literature
| S-EPMC6447416 | biostudies-literature
| S-EPMC3923075 | biostudies-literature
| S-EPMC5376042 | biostudies-literature
| S-EPMC6593884 | biostudies-literature
| S-EPMC3094047 | biostudies-literature
| S-EPMC3322979 | biostudies-literature
| S-EPMC5711342 | biostudies-literature
| S-EPMC11364750 | biostudies-literature
| S-EPMC8176143 | biostudies-literature